A new study shows that GLP-1 receptor agonist drugs, widely used for weight loss and treating metabolic diseases, may inadvertently affect human behavioral patterns and are associated with reduced risks of aggression and violent crime, adding a new dimension to the social impact of this "influencer weight loss drug".
GLP-1 receptor agonists (GLP-1 RA) were initially used to treat type 2 diabetes. Later, they quickly became popular under trade names such as Wegovy and Ozempic due to their remarkable effects in suppressing appetite and helping weight loss, and were regarded as a "miracle drug." Related research also continues to find that these drugs may have additional benefits in areas such as cardiovascular health, improved kidney function, and relief of sleep apnea. Its mechanism of action is relatively clear: the human intestine naturally secretes glucagon-like peptide-1, a hormone that can trigger a variety of physiological processes, including promoting the pancreas to secrete insulin and inhibiting the liver from releasing hormones that increase blood sugar, thereby helping to control blood sugar levels. GLP-1 receptor agonists mimic the activity of this hormone at the cell receptor level, achieving multiple effects such as limiting blood sugar, slowing gastric emptying, and reducing food intake.
Even more concerning, studies have found that GLP-1 drugs also appear to suppress "craving" behavior, which is not only reflected in the desire for food, but may also extend to other rewarding behaviors, such as dependence on drugs, alcohol and even gambling. With the rapid expansion of the population using such drugs, their potential effects on behavior have gradually become an important research direction in the fields of public health and social sciences. Daniel Semenza, a sociologist at Rutgers University in the United States, pointed out that as GLP-1 drugs become increasingly popular, clarifying their effects on a broader behavioral level has become an urgent issue in public health and criminology research.
The latest study, published in the academic journal Criminology, analyzed the relationship between alcohol use, impulsivity and violent criminal behavior based on questionnaire data from 821 adults conducted in the United States in 2025. The research team compared the strength of the association between the above variables in people who were current users of GLP-1 receptor agonist drugs with those who had previously used but were currently discontinued. Results showed that the association between alcohol use, impulsivity, and violent behavior was significantly attenuated among respondents who were using GLP-1 medications.
The researchers pointed out that even if simply reducing drinking behavior itself would help reduce the frequency of sudden violent incidents, this analysis found that even impulsive behavior that occurs under the influence of alcohol was less likely to escalate into actual violence among subjects who were currently using GLP-1 drugs. Semenza and his colleague Christopher Thomas, the authors of the paper, said in the report that although they remained cautious in interpreting the results due to limitations such as the cross-sectional design of the study and the data's reliance on self-reporting, these findings raise an important hypothesis: the use of GLP-1 receptor agonists may be changing the patterns of associations between impulsivity and violent behavior that have been widely documented in previous studies.
The current study does not directly explain the specific causal mechanisms behind the reduction in violent behavior, but other ongoing work is uncovering neural pathways in the brain related to reward and stress regulation that may play a key role. If these neural mechanisms are further clarified, it will help answer: In addition to adjusting metabolism and body weight, GLP-1 drugs are also "reshaping" the way some people deal with stress and temptation, thereby indirectly affecting crime risk.
The research team also emphasized that such findings should never be interpreted as a means of "controlling behavior" through drugs, let alone divert attention from community-level crime prevention efforts. In their view, the possible link between GLP-1 drugs and the risk of violence is more critical to remind society: when a drug used for a long time by millions of people around the world begins to show effects on mood regulation, impulse control, and even criminal behavior, understanding both the positive and negative sides of these effects is crucial to making informed health management decisions. The study, led by Rutgers University and published through peer review, is a new starting point in the discussion surrounding the social impact of GLP-1 drugs.
Related articles:
GLP‑1 weight-loss drug may offer new hope for adult asthma patients